A recent landmark analysis compared genome-wide mutations and associated 'omics' features for 3,281 tumours across 12 human cancer types. There is a clear need for objective target assessment and prioritization by the drug discovery community to make the best use of such vast amounts of data.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
Genome Medicine Open Access 31 May 2018
-
The current use and attitudes towards tumor genome sequencing in breast cancer
Scientific Reports Open Access 02 March 2016
-
TP53: an oncogene in disguise
Cell Death & Differentiation Open Access 29 May 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kandoth, C. et al. Mutational landscape and significance across 12 major cancer types. Nature 502, 333–339 (2013).
Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546–1558 (2013).
Futreal, P. A. et al. A census of human cancer genes. Nature Rev. Cancer 4, 177–183 (2004).
Patel, M. N. et al. Objective assessment of cancer genes for drug discovery. Nature Rev. Drug Discov. 12, 35–50 (2013).
Halling-Brown, M. D. et al. canSAR: an integrated cancer public translational research and drug discovery resource. Nucleic Acids Res. 40, D947–D956 (2012).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors work at The Institute of Cancer Research, London, UK, which has a commercial interest in the discovery and development of anticancer drugs.
Supplementary information
Supplementary information S1 (box)
Objective analysis of cancer genes (PDF 2031 kb)
Related links
Related links
FURTHER INFORMATION
International Cancer Genome Consortium
Rights and permissions
About this article
Cite this article
Workman, P., Al-Lazikani, B. Drugging cancer genomes. Nat Rev Drug Discov 12, 889–890 (2013). https://doi.org/10.1038/nrd4184
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd4184
This article is cited by
-
PanDrugs: a novel method to prioritize anticancer drug treatments according to individual genomic data
Genome Medicine (2018)
-
Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets
Nature Genetics (2018)
-
A comprehensive map of molecular drug targets
Nature Reviews Drug Discovery (2017)
-
The current use and attitudes towards tumor genome sequencing in breast cancer
Scientific Reports (2016)
-
TP53: an oncogene in disguise
Cell Death & Differentiation (2015)
